Repros Therapeutics Inc.
) lead pipeline candidate, Androxal, is being evaluated for the
treatment of patients with secondary hypogonadism. The company
received guidance from the U.S. Food and Drug Administration
(FDA) related to the Androxal development program on Oct 22,
Repros now expects to submit the new drug application (NDA) to
the U.S. Food and Drug Administration (FDA) in the fourth quarter
of 2014. Earlier, the company had planned on submitting the NDA
in mid-2014 with potential launch in 2015.
ABBVIE INC (ABBV): Free Stock Analysis Report
ACTELION LTD (ALIOF): Get Free Report
ROCHE HLDG LTD (RHHBY): Get Free Report
REPROS THERAPEU (RPRX): Free Stock Analysis
To read this article on Zacks.com click here.
Investors reacted negatively to the delay in the potential
approval of Repros. The stock price of Repros fell significantly
the following day. Though the stock price has recovered
marginally, overall the stock lost 24.6% since the announcement.
The FDA has requested a meeting to discuss the data from two
pivotal studies, ZA-301 and ZA-302 on Androxal. The FDA wants to
determine whether the company should include men referred from a
fertility clinic (site 9) in its final analysis of Study ZA-301.
We note that earlier this year, the company had announced
encouraging top-line data from the first pivotal phase III study
(ZA-301) and the second pivotal efficacy study (ZA-302). Both,
ZA-301 and ZA-302 - conducted under the FDA's Special Protocol
Assessment (SPA) program - had met the two their respective
As the FDA will consider different sperm endpoints than those
outlined in the SPA, the company plans to conduct two studies (12
weeks and 18 weeks) and finalize the design for the same.
The FDA has agreed to studies comparing Androxal to approved
testosterone replacement therapies. Repros stands to benefit from
the additional trials as data if positive can be added to the
Currently prescribed therapies for secondary hypogonadism include
Repros currently carries a Zacks Rank #3 (Hold). We expect
investor focus to remain on Androxal updates.
However, companies like
) look more attractive with a Zacks Rank #1 (Strong Buy).